4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Aurobindo Pharma Limited (AUROPHARMA) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hyderabad, India with about 29,209 employees. Its market capitalization is roughly ₹998 billion. In the fiscal year ended 2026-03-31, AUROPHARMA reported ₹333.8B in revenue and ₹35.0B in net income.
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Revenue | ₹333.8B | ₹313.8B | ₹287.0B | ₹246.2B |
| Gross Profit | ₹190.6B | ₹176.4B | ₹154.7B | ₹127.2B |
| Operating Income (EBIT) | ₹51.9B | ₹50.5B | ₹44.4B | ₹25.4B |
| Net Income | ₹35.0B | ₹34.9B | ₹31.7B | ₹19.3B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | ₹91.1B | ₹87.5B | ₹86.0B | ₹77.9B | ₹83.8B | — |
| Gross Profit | ₹54.8B | ₹53.2B | ₹51.2B | ₹45.5B | ₹49.5B | — |
| Operating Income (EBIT) | ₹13.9B | ₹13.2B | ₹13.1B | ₹12.0B | ₹13.5B | — |
| Net Income | ₹10.3B | ₹9.2B | ₹9.1B | ₹8.2B | ₹9.0B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹2.3B) | (₹10M) | (₹2.6B) | (₹4.4B) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹585.0B | ₹497.8B | ₹450.7B | ₹398.9B | — |
| Total Liabilities | ₹206.2B | ₹171.4B | ₹152.2B | ₹130.4B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AUROPHARMA viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms